logo
5 Best Supplements to Gain Weight

5 Best Supplements to Gain Weight

CNET05-05-2025
When it comes to working out, your end goal may be to lose weight. But if you struggle to keep on weight, want to pack on muscle or need a boost in pounds for sports or lifestyle, there are certain foods and supplements that can help you attain your goals.
Several factors play into your body's ability to gain weight, such as age, gender, genetics, diseases and physical activity. It should be noted that if you want to gain weight, you should first start by gaining muscle.
Here are the best supplements, nutrients and vitamins you should take to gain weight and muscle.
What to look for in your weight gain supplements
Finding the right supplements to gain weight can be tricky. Here are a few tips to navigate the many options.
Verifications : Look for vitamins and supplements that have official certifications. In the US, the Dietary Supplement Verification Program ensures any product with a USP-verified label contains accurate, pure ingredients and has been manufactured using Good Manufacturing Practices. NSF International certifies products for label and content accuracy, checks for purity and contaminants and audits the manufacturing process for Good Manufacturing Practices compliance. The Consumer Lab also tests supplements for accuracy of ingredient identity, content and purity. Lastly, the Natural Products Association also has a Good Manufacturing program.
: Look for vitamins and supplements that have official certifications. In the US, the Dietary Supplement Verification Program ensures any product with a USP-verified label contains accurate, pure ingredients and has been manufactured using Good Manufacturing Practices. NSF International certifies products for label and content accuracy, checks for purity and contaminants and audits the manufacturing process for Good Manufacturing Practices compliance. The Consumer Lab also tests supplements for accuracy of ingredient identity, content and purity. Lastly, the Natural Products Association also has a Good Manufacturing program. Dietary restrictions : If you have dietary restrictions, look for supplements that do not contain the ingredients you want to avoid like milk, egg, soy, gluten or shellfish. There are also supplements that are made for vegetarians and vegans.
: If you have dietary restrictions, look for supplements that do not contain the ingredients you want to avoid like milk, egg, soy, gluten or shellfish. There are also supplements that are made for vegetarians and vegans. Non-GMO: The best supplements will be non-GMO and have no added sugars, colors or dyes.
Best supplements for weight gain
Huizeng Hu/Moment/Getty Images
These are our top five supplements to gain weight that are worth your money.
Protein powder
The first place to start if you're looking to gain weight is your protein. If you prefer to not take any protein powders, you can try increasing the amount of protein-rich foods in your diet. These include:
Beef, lamb, chicken and pork
Eggs
Dairy
Nuts
Soy
Fish
However, you might find it easier to add protein shakes to your workout routine. Whey protein is an easy way to exponentially increase your protein intake. Studies show that whey protein helps increase lean body mass and muscle.
Creatine
Creatine is an amino acid that provides energy directly to the body and creates the energy compound adenosine triphosphate. ATP helps the muscles quickly contract during workouts. Creatine is found naturally in red meats, poultry and fish.
Creatine is available in powder or pill form and can be flavored. It can be taken before or after a meal, and it is recommended to stay hydrated during the day. Studies have found that creatine is effective in long- and short-term muscle growth and improved athletic performance. However, individuals with suspected renal dysfunction should refrain from creatine supplementation.
Fats and carbohydrates
It's no secret that fats and carbohydrates help increase your body mass. There are three categories of fats -- unsaturated fats, saturated fats and trans fats. Unsaturated fats are considered "good fats," and studies have found that these fats can help increase muscle and overall mass. "Good fats" can be found naturally in foods such as:
Salmon, tuna
Avocados
Olive, canola and peanut oils
Peanuts, almonds, hazelnuts and pecans
Pumpkin, sunflower and sesame seeds
Carbohydrates are transformed into energy, which is essential for working out and exercising. Studies suggest that carbohydrates and protein work together to increase muscle mass. Carbohydrates can be found naturally in foods such as:
Bread
Beans
Milk
Grains
Pasta
Fruit
Thiamine (B1)
Vitamins and micronutrients don't naturally contain any calories, so they cannot contribute to weight gain. However, if you're deficient in specific vitamins, such as thiamine, weight gain may be more difficult. A deficiency in thiamine can suppress your appetite and cause fatigue, therefore making it harder to eat more and build body and muscle mass. Thiamine is found naturally in foods such as:
Enriched white egg or rice noodles
Pork
Black beans
Yogurt
Corn
Sunflower seeds
If you're deficient or lacking in B vitamins, consider a supplement.
Iron
An iron deficiency also may decrease your appetite. Iron is important for your red blood cells and the transportation of oxygen. This nutrient is found naturally in foods such as:
Red meats
Beans
Nuts
Dried fruits
Fortified cereals
If you're deficient or lacking in iron, consider a supplement.
Bottom line
If you want to increase your body mass, the most important steps are to take in more calories and work out. This way, you will have more energy to burn while exercising and you should pack on muscle. It's healthier to have more of your body weight come from muscle than fat.
In addition to these two important steps, you can add certain supplements, nutrients and vitamins to your diet or exercise routine. Protein in the form of foods, such as meats, nuts, eggs or dairy, or the form of powders, shakes or supplements is a great place to start. Creatine powder is also often used as an after-workout shake. Fats and carbohydrates, vitamin B1 and iron are also good additions to any meal that you may already be making, especially if you are deficient.
If you aren't getting enough vitamins or nutrients from your regular day-to-day diet, vitamin supplements are recommended. It might be the extra boost you're looking for.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034

Yahoo

timea day ago

  • Yahoo

U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034

The U.S. pharmaceutical CDMO market is estimated at USD 39.14 billion in 2025 and is projected to reach approximately USD 68.57 billion by 2034, expanding at a CAGR of 6.43% over the forecast period. Ottawa, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister firm of Precedence Research, the U.S. pharmaceutical CDMO market was valued at USD 36.77 billion in 2024 and is projected to reach approximately USD 68.57 billion by 2034, growing at a CAGR of 6.43%. The rising commercial scale-up in different therapeutic areas in the US and growing adoption of digital technologies are fueling overall market expansion. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways By product, the API segment dominated the U.S. pharmaceutical CDMO market in 2024 and is expected to grow fastest during the forecast period. By workflow, the commercial segment held the largest revenue share of the market in 2024. By application, the oncology segment registered dominance in the market in 2024. By end-use, the large pharmaceutical companies segment was dominant in the U.S. pharmaceutical CDMO market in 2024 and is expected to grow rapidly in the studies years. Market Overview & Potential Companies that are offering comprehensive services to different pharmaceutical and biotechnology companies, including both drug development and manufacturing in the US, are referred to as U.S. pharmaceutical CDMO market. Primarily, they provide expertise and resources for these companies. In 2025, they are focusing on novel drug discovery and development in oncology and other chronic conditions with the increased adoption of advanced production technologies. Moreover, the US is widely investing in robust and advanced infrastructure to fulfil the requirements of the increasing demand for specialized services, particularly in areas like biologics, sterile injectables, and gene and cell therapies. What are the Key Drivers Involved in The Growth of The Market? The U.S. pharmaceutical CDMO market has major dominating factors in its expansion, including crucial support to small and mid-sized pharmaceutical companies. These companies are facing the limitations of infrastructure for large-scale production with enhanced dependence on CDMOs for numerous stages of development and manufacturing. Also, benefits of pharmaceutical CDMOs, like scalability, flexibility, and cost-effectiveness, are fueling the expansion of the market with reduced capital investments. Besides this, experts working in CDMOs can navigate the complex regulatory landscape and check the compliance with standards like GMP (Good Manufacturing Practices). What are the Trends Associated with the U.S. Pharmaceutical CDMO Market? Different companies in the US are highly adopting outsourcing production to CDMOs to handle expenses and emphasis on competencies. Alongside, continuous advances in technologies and regulatory frameworks also play a crucial role in this market development. In May 2025, CDMO Piramal Pharma Solutions announced $90 million investment into its US manufacturing facilities. In March 2025, LGM Pharma, a global provider of customized API and CDMO services for the full drug product lifecycle, invested $6M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Emerging Challenge in the Market? Challenges connected with the U.S. pharmaceutical CDMO market include geopolitical stress, lack of raw material, and pandemic-related disturbances, are contribute as barriers in the production and delivery. Along with this, the rising need for a skilled workforce and specialized knowledge in continuous manufacturing and advanced bioprocessing demands vital investment in training and development. Country-level Analysis The U.S. pharmaceutical CDMO market is experiencing widespread expansion due to broader demand for a variety of biologics and biosimilars which are used in novel rare cases and other severe health issues. Besides this, ongoing technological breakthroughs in process chemistry and manufacturing automation are boosting the efficiency and quality of drug production, further propelling the adoption of CDMO services. As well as escalating cases of diverse cancers is assisting the development of novel cancer therapies, including targeted therapies and immunotherapies. For this market, In June 2025, Agenus Inc., a U.S.-based biotechnology company specializing in immuno-oncology, entered into a partnership with $141M Zydus investment to transform the immune-oncology area. Segmental Insights By product analysis How did the API Segment Lead the U.S. Pharmaceutical CDMO Market in 2024? The API segment was dominant in the market in 2024 and will grow rapidly during 2025-2034. An escalating demand for both traditional and complex APIs, especially in small molecule drugs, is fueling the segment's growth. In this segment, synthetic APIs experienced major demand, which are highly employed in numerous therapeutic areas such as cardiovascular, analgesic, and CNS drugs, making them an important driver in the API CDMO market. Also, this segment is moving towards continuous manufacturing, process analytical technology (PAT), sustainability, and digitalization, with enhanced focus on specialized CDMOs catering to niche therapeutic areas and expansion in biotech API development. Become a valued research partner with us - By workflow analysis What Made the Commercial Segment Dominant in the Market in 2024? In the U.S. pharmaceutical CDMO market, the commercial segment captured a major revenue share in 2024. Across the globe, one of the vital factors contributing to the overall market expansion is improved focus on the large-scale manufacturing of pharmaceuticals and biopharmaceuticals for commercial distribution. Moreover, widespread involvement of specialized expertise in biologics, cell & gene therapies, and mRNA vaccines necessitates sophisticated and specialized manufacturing capabilities. Additionally, CDMOs are boosting their service offerings by expanding collaboration with other organizations and companies to incorporate the complete drug development and manufacturing lifecycle, from early development to commercial launch. By application analysis How did Oncology Dominate the U.S. Pharmaceutical CDMO Market in 2024? The oncology segment registered dominance with the biggest share of the market in 2024. Eventual growth in cancer cases, with the progression of personalized therapies and targeted treatments, is impacting segment expansion. US CDMOs are stepping towards the transformation of advanced therapies, especially cell and gene therapies, antibody-drug conjugates, and bispecific antibodies, which are a major part of oncology clinical trials. These therapies are widely propelling demand for specialized facilities and expertise in handling potent APIs, cytotoxic compounds, and sterile injectables. By end-use analysis How did the Large Pharmaceutical Companies Hold a Major Share of The Market in 2024? The large pharmaceutical companies segment led the U.S. pharmaceutical CDMO market in 2024 and is anticipated to witness the fastest growth during 2025-2034. Nowadays, a rise in innovation investments, mainly in data analytics and AI, is assisting overall drug development processes and ultimately enhancing productivity. Apart from this, these companies are focusing on the utilization of advanced formulation technologies in specific areas, especially oral peptide formulations and permeation enhancers, to optimize drug delivery. These companies frequently grasp their robust infrastructure, scientific expertise, and global networks, which make them attractive for further collaborations and outsourcing to CDMOs in the US. Get the latest insights on healthcare industry segmentation with our Annual Membership: Ongoing Developments in the U.S. Pharmaceutical CDMO Market In July 2025, ESTEVE acquired Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), to accelerate its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. In May 2025, Purdue University and a collaboration of leaders in AI, pharmaceutical manufacturing, and public policy launched a national effort in the Dirksen Senate Office Building to boost pharmaceutical manufacturing in the United States by revealing cutting-edge AI and advanced manufacturing technologies. In May 2025, Benuvia Operations, LLC, a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier, signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to support the company's product development activities. Key Players in the U.S. Pharmaceutical CDMO Market Adare Pharma Solutions AGC Biologics Agilent Technologies Catalent Pharma Solutions Exela Pharma Sciences PCI Pharma Services Pfizer CentreOne Scorpius BioManufacturing Sharp Services Single Use Support Thermo Fisher Scientific UPM Pharmaceuticals, Inc. Browse More Insights of Towards Healthcare: The global bioconjugation market reached USD 5.52 billion in 2024, rose to USD 6.37 billion in 2025, and will likely hit USD 23.18 billion by 2034, expanding at a CAGR of 15.46% from 2025 to 2034. The U.S. residual DNA testing market continues its upward trajectory and is set to generate substantial revenue growth, potentially reaching hundreds of millions by 2034. The worldwide life science CDMO market is expanding significantly and is projected to record several hundred million dollars in additional revenue by the end of the forecast period from 2025 to 2034. The global veterinary CRO and CDMO market stood at USD 7.17 billion in 2024, increased to USD 7.77 billion in 2025, and will likely reach USD 16.13 billion by 2034, growing at a CAGR of 8.43% between 2025 and 2034. The global investigational new drug CDMO market measured USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is forecast to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% during the same period. The global advanced therapy medicinal products CDMO market stood at USD 6.73 billion in 2024, grew to USD 7.99 billion in 2025, and will likely surge to USD 37.27 billion by 2034, posting a CAGR of 18.82% between 2025 and 2034. The global mRNA therapeutics CDMO market valued at USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37% from 2025 to 2034. The CDMO services for pharma and biotech market is posting substantial growth from 2024 to 2034, fueled by rising outsourcing trends among pharmaceutical and biotech companies. The CDMO aseptic filling solutions market is recording robust growth and will continue booming through the forecast period, driven by growing demand for sterile manufacturing and specialized injectable therapies. The active pharmaceutical ingredients CDMO market stood at USD 127.45 billion in 2024, rose to USD 136.92 billion in 2025, and is projected to reach USD 260.98 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. Segments Covered in The Report By Product API Type Traditional API Highly Potent API Antibody-drug conjugate (ADC) Others Synthesis Synthetic Solid Liquid Biotech Drug Innovative Generics Manufacturing Continuous Manufacturing Batch Manufacturing Drug Product Oral Solid Dose Semi-Solid Dose Liquid Dose Others By Workflow Commercial Clinical By Application Oncology Small Molecules Biologics Infectious Diseases Neurological Disorders Cardiovascular Disease Metabolic Disorders Autoimmune Diseases Respiratory Diseases Ophthalmology Gastrointestinal Disorders Hormonal Disorders Hematological Disorders Others By End-Use Large Pharmaceutical Companies Medium Pharmaceutical Companies Small Pharmaceutical Companies Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Best Vitamins and Supplements for Women in 2025
Best Vitamins and Supplements for Women in 2025

CNET

time05-08-2025

  • CNET

Best Vitamins and Supplements for Women in 2025

Nature Made makes some of the most affordable vitamins available. The Nature Made women's multivitamin includes 23 nutrients essential for women, including 100% of the recommended daily value of iron. Iron is one of the most common deficiencies in women, especially when pregnant or menstruating. With Nature Made, you get over the recommended value of vitamin C, D3 and E, as well as minerals zinc, copper and chromium. So if you are not deficient in those areas, you could get too much of them. Consuming too much vitamin D or E can result in toxicity. Nature Made doesn't have the additional bells and whistles other options on the list do, like probiotics. It's a dependable multivitamin that established a name for itself long ago. You also can get Nature Made multivitamins for women at every stage of their life -- prenatal, postnatal and over 50. You can trust the quality of Nature Made because all products are third-party tested and USP-verified.

Sunflower Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S
Sunflower Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S

Business Wire

time23-07-2025

  • Business Wire

Sunflower Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S

MEDFORD, Mass.--(BUSINESS WIRE)-- Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower's first commercial partnership in Europe, representing a key step in its international growth strategy. 'Expanding into Europe with a trusted and innovative partner like Alflow allows us to support a broader community of scientists and biomanufacturers,' said Dr. Kerry Love, CEO and co-founder of Sunflower Therapeutics. "Alflow's team brings a deep technical knowledge that aligns with our ongoing product commercialization goals and our objective of making protein manufacturing more intuitive, cost-effective, and efficient. We're excited to work with their team to bring our technology overseas to new markets.' Sunflower's innovative Daisy Petal™ is a breakthrough technology designed for high-efficiency protein production using an intuitive, single-use assembly. The system features a disposable stirred tank reactor with an integrated in-vessel cell retention device that enables continuous biomass feeding, fluid harvesting, and perfusion, which results in significantly higher space-time yields compared to traditional fed-batch fermentation. 'Partnering with Sunflower Therapeutics allows us to bring a truly novel bioreactor solution to the Nordic market,' said Jacob Rosenkrands, CEO of Alflow Scandinavia A/S. 'We are committed to offering our customers solutions that make a measurable difference. The Daisy Petal system stands out by combining simplicity, scalability, and performance – and we look forward to supporting our customers in bringing it into practice.' Sunflower's bioprocessing software suite, compliant with Good Manufacturing Practices (GMP) for use in regulated biomanufacturing, includes HelianthOS™, Nursery™, and Harvest™. These tools enable walkaway automation of fermentation processes, easy development of process recipes with no coding, and the secure storage of process data generated by the Daisy Petal™ System. Together, these three elements provide a cohesive ecosystem that enables efficient and intuitive operations throughout an entire campaign. To learn more about the Daisy Petal™, contact Alflow Scandinavia A/S at About Sunflower Therapeutics Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods and Contract Research Organization (CRO) services for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing. About Alflow Scandinavia A/S Alflow Scandinavia A/S is a Danish team of flow technology experts that delivers high-quality components, technical advice, and works in close collaboration with customers in the pharma, food, and single-use industries. With more than 25 years of experience, the company turns expertise into reliable solutions that create value, ensure safety – and deliver flow that makes a difference. Visit:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store